Statement: Cancer treatments and ovarian reserve;Mise au point: Traitements anticancéreux et réserve ovarienne

Journal de Gynecologie Obstetrique et Biologie de la Reproduction

Volumn 39, Issue 6, 2010, Pages 433-443

  Basille, C ^a,b   Torre, A ^a,b   Grynberg, M ^a,b   Gallot, V ^a,b   Frydman, R ^a,b,c   Fanchin, R ^a,b,c  

^a UNIVERSITÉ PARIS SACLAY   (France)

^b HÔPITAL ANTOINE BÉCLÈRE   (France)

^c INSERM   (France)

Author keywords

Chemotherapy; Fertility; Ovarian reserve; Radiotherapy

Indexed keywords

ANTHRACYCLINE; ANTINEOPLASTIC AGENT; BLEOMYCIN; BUSULFAN; CHLORAMBUCIL; CISPLATIN; CYCLOPHOSPHAMIDE; DACTINOMYCIN; DOXORUBICIN; FLUOROURACIL; MELPHALAN; METHOTREXATE; PROCARBAZINE; VINBLASTINE; VINCA ALKALOID; VINCRISTINE;

CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER THERAPY; CRYOPRESERVATION; FERTILITY; HUMAN; MENSTRUATION; MUTAGENIC ACTIVITY; OSTEOSARCOMA; OVARIAN RESERVE; OVARY FUNCTION; OVARY INSUFFICIENCY; REPRODUCTIVE TOXICITY; REVIEW; UTERUS CANCER;

ANTI-MULLERIAN HORMONE; ANTINEOPLASTIC AGENTS; BIOLOGICAL MARKERS; CRYOPRESERVATION; FEMALE; FERTILITY; GONADOTROPIN-RELEASING HORMONE; HUMANS; INFERTILITY, FEMALE; NEOPLASMS; OVARY; REPRODUCTIVE TECHNIQUES, ASSISTED;

EID: 77957820602     PISSN: 03682315     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jgyn.2010.05.012     Document Type: Review

References (135)

1. M.F. Brougham, and W.H. Wallace Subfertility in children and young people treated for solid and haematological malignancies Br J Haematol 131 2005 143 155
2. K. Oktay, and M. Sönmezer Chemotherapy and amenorrhea: risks and treatment options Curr Opin Obstet Gynecol 20 2008 408 415
3. P. This Breast cancer and fertility: critical review, considerations and perspectives Bull Cancer 95 2008 17 25
4. H. Brincker, C. Rose, F. Rank, H.T. Mouridsen, A. Jakobsen, and P. Dombernowsky Evidence of a castration-mediated effect of adjuvant cytotoxic chemotherapy in premenopausal breast cancer J Clin Oncol 5 1987 1771 1778
5. K. Ataya, and K. Moghissi Chemotherapy-induced premature ovarian failure: mechanisms and prevention Steroids 54 1989 607 626
6. H.R. Franke, W.M. Smit, and I. Vermes Gonadal protection by a gonadotropin-releasing hormone agonist depot in young women with Hodgkin's disease undergoing chemotherapy Gynecol Endocrinol 20 2005 274 278
7. A. Partridge, S. Gelber, R.D. Gelber, M. Castiglione-Gertsch, A. Goldhirsch, and E. Winer Age of menopause among women who remain premenopausal following treatment for early breast cancer: long-term results from International Breast Cancer Study Group Trials V and VI Eur J Cancer 43 2007 1646 1653
8. J. Byrne, T.R. Fears, and M.H. Gail Early menopause in long term survivors of cancer during adolescence Am J Obstet Gynecol 166 1992 788 793
9. D. Meirow Reproduction post-chemotherapy in young cancer patients Mol Cell Endocrinol 169 2000 123 131
10. Early Breast Cancer Trialists' Collaborative Group. Polychemotherapy for early breast cancer: an overview of the randomised trials Lancet 352 1998 930 942
11. L.B. Wenzel, D.L. Fairclough, M.J. Brady, D. Cella, K.M. Garrett, and B.C. Kluhsman Age-related differences in the quality of life of breast carcinoma patients after treatment Cancer 86 1999 1768 1774 (Pubitemid 29513046)
12. J. Mancini, D. Rey, M. Préau, L. Malavolti, and J.P. Moatti Infertility induced by cancer treatment: inappropriate or no information provided to majority of French survivors of cancer Fertil Steril 90 2008 1616 1625
13. T. Falcone, and M.A. Bedaiwy Fertility preservation and pregnancy outcome after malignancy Curr Opin Obstet Gynecol 17 2005 21 26
14. A.M. Chiarelli, L.D. Marrett, and G. Darlington Early menopause and infertility in females after treatment for childhood cancer diagnosed in 1964-1988 in Ontario Canada Am J Epidemiol 150 1999 245 254
15. O. Oktem, and K. Oktay Quantitative assessment of the impact of chemotherapy on ovarian follicle reserve and stromal function Cancer 110 2007 2222 2229 (Pubitemid 350100744)
16. O. Oktem, and K. Oktay A novel ovarian xenografting model to characterize the impact of chemotherapy agents on human primordial follicle reserve Cancer Res 67 2007 10159 10162
17. E. Whitehead, S.M. Shalet, P.H. Jones, C.G. Beardwell, and D.P. Deakin Gonadal function after combination chemotherapy for Hodgkin's disease in childhood Arch Dis Child 57 1982 287 2891
18. E. Whitehead, S.M. Shalet, G. Blackledge, I. Todd, D. Crowther, and C.G. Beardwell The effect of combination chemotherapy on ovarian function in women treated for Hodgkin's disease Cancer 52 1983 988 993
19. W.H. Wallace, S.M. Shalet, E.C. Crowne, P.H. Morris-Jones, H.R. Gattamaneni, and D.A. Price Gonadal dysfunction due to cis-platinum Med Pediatr Oncol 17 1989 409 413
20. W.H. Wallace, S.M. Shalet, M. Lendon, and P.H. Morris-Jones Male fertility in long-term survivors of childhood acute lymphoblastic leukaemia Int J Androl 14 1991 312 319
21. J. Byrne Infertility and premature menopause in childhood cancer survivors Med Pediatr Oncol 33 1999 24 28
22. D. Meirow Ovarian injury and modern options to preserve fertility in female cancer patients treated with high dose radio-chemotherapy for hemato-oncological neoplasias and other cancers Leuk Lymphoma 33 1999 65 76
23. J.A. Petrek, M.J. Naughton, L.D. Case, E.D. Paskett, E.Z. Naftalis, and S.E. Singletary Incidence, time course, and determinants of menstrual bleeding after breast cancer treatment: a prospective study J Clin Oncol 24 2006 1045 1051
24. E.C. Larsen, J. Muller, K. Schmiegelow, C. Rechnitzer, and A.N. Andersen Reduced ovarian function in long-term survivors of radiation- and chemotherapy-treated childhood cancer J Clin Endocrinol Metab 88 2003 5307 5314
25. R.L. Schilsky, R.J. Sherins, S.M. Hubbard, M.N. Wesley, R.C. Young, and V.T. DeVita Long-term follow-up of ovarian function in women treated with MOPP chemotherapy for Hodgkin's disease Am J Med 71 1981 552 556
26. X. Wu, F.D. Groves, C.C. McLaughlin, A. Jemal, J. Martin, and V.W. Chen Cancer incidence patterns among adolescents and young adults in the United States Cancer Causes Control 16 2005 309 320
27. A. Jemal, R. Siegel, E. Ward, T. Murray, J. Xu, and M.J. Thun Cancer statistics, 2007 CA Cancer J Clin 57 2007 43 66
28. S.E. Minton, and P.N. Munster Chemotherapy-induced amenorrhea and fertility in women undergoing adjuvant treatment for breast cancer Cancer Control 9 2002 466 472
29. A.R. Bianco, L. Del Mastro, C. Gallo, F. Perrone, E. Matano, and C. Pagliarulo Prognostic role of amenorrhea induced by adjuvant chemotherapy in premenopausal patients with early breast cancer Br J Cancer 63 1991 799 803
30. J.M. Walshe, N. Denduluri, and S.M. Swain Amenorrhea in premenopausal women after adjuvant chemotherapy for breast cancer J Clin Oncol 24 2006 5769 5779
31. M. Sonmezer, and K. Oktay Fertility preservation in young women undergoing breast cancer therapy Oncologist 11 2006 422 434 (Pubitemid 43788268)
32. A. Reh, O. Oktem, and K. Oktay Impact of breast cancer chemotherapy on ovarian reserve: a prospective observational analysis by menstrual history and ovarian reserve markers Fertil Steril 90 2008 1635 1639
33. S. Lee, L. Schover, A. Partridge, P. Patrizio, W.H. Wallace, and K. Hagerty American society of clinical oncology recommendations on fertility preservation in cancer patients J Clin Oncol 18 2006 1 15
34. S.E. Waggoner Cervical cancer Lancet 361 2003 2217 2225
35. F.B. Stehman, P.G. Rose, B.J. Greer, M. Roy, M. Plante, and M. Penalver Innovations in the treatment of the uterine cervix Cancer 98 2003 2052 2063
36. X.J. Martin, F. Golfier, P. Romestaing, and D. Raudrant First case of pregnancy after radical trachelectomy and pelvic irradiation Gynecol Oncol 74 1999 286 287
37. D. Dargent, X. Martin, A. Sacchetoni, and P. Mathevet Laparoscopic vaginal radical trachelectomy: a treatment to preserve the fertility of cervical carcinoma patients Cancer 88 2000 1877 1882
38. M. Roy, and M. Plante Pregnancies after radical vaginal trachelectomy for early-stage cervical cancer Am J Obstet Gynecol 179 1998 1491 1496
39. C. Haie-Meder, B. Fervers, E. Fondrinier, M. Haugh, C. Lhomme, and J.P. Guastalla SOR guidelines for concomitant chemoradiotherapy for patients with uterine cervical cancers: evidence update bulletin 2004 Ann Oncol 16 2005 1100 1108
40. F. Peccatori, C. Bonazzi, S. Chiari, F. Landoni, N. Colombo, and C. Mangioni Surgical management of malignant ovarian germ-cell tumors: 10 years' experience of 129 patients Obstet Gynecol 86 1995 367 372
41. D.M. Gershenson Menstrual and reproductive function after treatment with combination chemotherapy for malignant ovarian germ cell tumors J Clin Oncol 6 1988 270 275
42. K. Kanazawa, T. Suzuki, and K. Sakumoto Treatment of malignant ovarian germ cell tumors with preservation of fertility: reproductive performance after persistent remission Am J Clin Oncol 23 2000 244 248
43. J. Gaffan, L. Holden, E.S. Newlands, D. Short, S. Fuller, and R.H. Begent Infertility rates following POMB/ACE chemotherapy for male and female germ cell tumours - a retrospective long-term follow-up study Br J Cancer 89 2003 1849 1854
44. J. Tangir, D. Zelterman, W. Ma, and P.E. Schwartz Reproductive function after conservative surgery and chemotherapy for malignant germ cell tumors of the ovary Obstet Gynecol 101 2003 251 257
45. Zanetta G, Bonazzi C, Cant M, Binidagger S, Locatelli A, Bratina G, et al. Survival and reproductive function after treatment of malignant germ cell ovarian tumors. J Clin Oncol 2001;19:1015-20.
46. L.R. Duska, Y.C. Chang, C.E. Flynn, A.H. Chen, A. Goodman, and A.F. Fuller Epithelial ovarian carcinoma in the reproductive age group Cancer 85 1999 2623 2629
47. P. Morice, S. Camatte, J. El Hassan, P. Pautier, P. Duvillard, and D. Castaigne Clinical outcomes and fertility after conservative treatment of ovarian borderline tumors Fertil Steril 75 2001 92 96
48. S. Camatte, P. Morice, P. Pautier, D. Atallah, P. Duvillard, and D. Castaigne Fertility results after conservative treatment of advanced stage serous borderline tumour of the ovary BJOG 109 2002 376 380
49. A. Farthing Conserving fertility in the management of gynaecological cancers BJOG 113 2006 129 134
50. C. Borgfeldt, C. Iosif, and A. Msbäck Fertility-sparing surgery and outcome in fertile women with ovarian borderline tumors and epithelial invasive ovarian cancer Eur J Obstet Gynecol Reprod Biol 134 2007 110 114
51. V. Kesic Fertility after the treatment of gynecologic tumors Recent Results Cancer Res 178 2008 79 95
52. J.M. Schilder, A.M. Thompson, P.D. DePriest, F.R. Ueland, M.L. Cibull, and R.J. Kryscio Outcome of reproductive age women with stage IA or IC invasive epithelial ovarian cancer treated with fertility sparing therapy Gynecol Oncol 87 2002 1 7
53. P. Morice, E. Leblanc, A. Rey, M. Baron, D. Querleu, and J. Blanchot GCCLCC and SFOG. Conservative treatment in epithelial ovarian cancer: results of a multicentre study of the GCCLCC (Groupe des chirurgiens de centre de lutte contre le cancer) and SFOG (Société francaise d'oncologie gynécologique) Hum Reprod 20 2005 1379 1385
54. J.Y. Park, D.Y. Kim, D.S. Suh, J.H. Kim, Y.M. Kim, and Y.T. Kim Outcomes of fertility-sparing surgery for invasive epithelial ovarian cancer: oncologic safety and reproductive outcomes Gynecol Oncol 110 2008 345 353
55. E.J. Dann, R. Epelbaum, I. Avivi, M. Ben Shahar, N. Haim, and J.M. Rowe Fertility and ovarian function are preserved in women treated with an intensified regimen of cyclophosphamide, adriamycin, vincristine and prednisone (Mega-CHOP) for non-Hodgkin lymphoma Hum Reprod 20 2005 2247 2249
56. A. Grigg The impact of conventional and high-dose therapy for lymphoma on fertility Clin Lymphoma 5 2004 84 88
57. K. Behringer, K. Breuer, T. Reineke, M. May, L. Nogova, and B. Klimm Secondary amenorrhea after Hodgkin's lymphoma is influenced by age at treatment, stage of disease, chemotherapy regimen, and the use of oral contraceptives during therapy: a report from the German Hodgkin's Lymphoma Study Group J Clin Oncol 23 2005 7555 7564
58. E. Brusamolino, F. Lunghi, E. Orlandi, C. Astori, F. Passamonti, and C. Baraté Treatment of early-stage Hodgkin's disease with four cycles of ABVD followed by adjuvant radio-therapy: analysis of efficacy and long-term toxicity Haematologica 85 2000 1032 1039
59. E. Brusamolino, A. Baio, E. Orlandi, L. Arcaini, F. Passamonti, and V. Griva Long-term events in adult patients with clinical stage IA-IIA non-bulky Hodgkin's lymphoma treated with four cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine and adjuvant radiotherapy: a single-institution 15-year follow-up Clin Cancer Res 12 2006 6487 6493
60. S.J. Horning, R.T. Hoppe, H.S. Kaplan, and S.A. Rosenberg Female reproductive potential after treatment for Hodgkin's disease N Engl J Med 304 1981 1377 1382
61. S.T. Clark, J.A. Radford, D. Crowther, R. Swindell, and S.M. Shalet Gonadal function following chemotherapy for Hodgkin's disease: a comparative study of MVPP and a seven-drug hybrid regimen J Clin Oncol 13 1995 134 139
62. C. Teinturier, O. Hartmann, D. Valteau-Couanet, E. Benhamou, and P.F. Bougneres Ovarian function after autologous bone marrow transplantation in childhood: high-dose busulfan is a major cause of ovarian failure Bone Marrow Transplant 22 1998 989 994
63. E. Thibaud, K. Rodriguez-Macias, C. Trivin, H. Espérou, J. Michon, and R. Brauner Ovarian function after bone marrow transplantation during childhood Bone Marrow Transplant 21 1998 287 290 (Pubitemid 28052232)
64. J.F. Apperley, and N. Reddy Mechanism and management of treatment-related gonadal failure in recipients of high dose chemoradiotherapy Blood Rev 9 1995 93 116
65. S.N. Rahhal, and E.A. Eugster Unexpected recovery of ovarian function many years after bone marrow transplantation J Pediatr 152 2008 289 290
66. R. Chatterjee, W. Mills, M. Katz, H.H. McGarrigle, and A.H. Goldstone Prospective study of pituitary-gonadal function to evaluate short-term effects of ablative chemotherapy or total body irradiation with autologous or allogenic marrow transplantation in post-menarcheal female patients Bone Marrow Transplant 13 1994 511 517
67. K. Winkler, G. Beron, G. Delling, U. Heise, H. Kabisch, and C. Purfürst Neoadjuvant chemotherapy of osteosarcoma: results of a randomized cooperative trial (COSS-82) with salvage chemotherapy based on histological tumor response J Clin Oncol 6 1988 329 337
68. H.S. Hosalkar, K.M. Henderson, A. Weiss, R. Donthineni, and R.D. Lackman Chemotherapy for bone sarcoma does not affect fertility rates or childbirth Clin Orthop Relat Res 428 2004 256 260
69. D.B. Greenberg, A. Goorin, M.C. Gebhardt, L. Gupta, N. Stier, and D. Harmon Quality of life in osteosarcoma survivors Oncology 8 1994 19 25
70. G. Bacci, S. Ferrari, F. Bertoni, P. Ruggieri, P. Picci, and A. Longhi Long-term outcome for patients with nonmetastatic osteosarcoma of the extremity treated at the istituto ortopedico rizzoli according to the istituto ortopedico rizzoli/osteosarcoma-2 protocol: an updated report J Clin Oncol 18 2000 4016 4027
71. J.Y. Blay Targeted therapies of cancer: not lost in translation Bull Cancer 93 2006 799 804
72. I. Smith, M. Procter, R.D. Gelber, S. Guillaume, A. Feyereislova, and M. Dowsett HERA study team. 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial Lancet 369 2007 29 36
73. M. Nurmio, J. Kallio, J. Toppari, and K. Jahnukainen Adult reproductive functions after early postnatal inhibition by imatinib of the two receptor tyrosine kinases, c-kit and PDGFR, in the rat testis Reprod Toxicol 25 2008 442 446
74. R.G. Gosden, J.C. Wade, H.M. Fraser, J. Sandow, and M.J. Faddy Impact of congenital or experimental hypogonadotrophism on the radiation sensitivity of the mouse ovary Hum Reprod 12 1997 2483 2488
75. R. Himelstein-Braw, H. Peters, and M. Faber Morphological study of the ovaries of leukaemic children Br J Cancer 38 1978 82 87
76. W.H. Wallace, A.B. Thomson, and T.W. Kelsey The radiosensitivity of the human oocyte Hum Reprod 18 2003 117 121
77. G. Socié, N. Salooja, A. Cohen, A. Rovelli, E. Carreras, and A. Locasciulli Late effects working party of the European study group for blood and marrow transplantation. Non malignant late effects after allogenic stem cell transplantation Blood 101 2003 3373 3385
78. C.C. Lushbaugh, and G.W. Casarett The effects of gonadal irradiation in clinical radiation therapy: a review Cancer 37 1976 1111 1125
79. W.H. Wallace, A.B. Thomson, F. Saran, and T.W. Kelsey Predicting age of ovarian failure after radiation to a field that includes the ovaries Int J Radiat Oncol Biol Phys 62 2005 738 744
80. T. Maltaris, H. Koelbl, R. Seufert, F. Kiesewetter, M.W. Beckmann, and A. Mueller Gonadal damage and options for fertility preservation in female and male cancer survivors Asian J Androl 8 2006 515 533
81. J. Arnon, D. Meirow, H. Lewis-Roness, and A. Ornoy Genetic and teratogenic effects of cancer treatments on gametes and embryos Hum Reprod Update 7 2001 394 403
82. R.A. Cowles, R.M. Gewanter, and J.J. Kandel Ovarian repositioning in pediatric cancer patients: flexible techniques accommodate pelvic radiation fields Pediatr Blood Cancer 49 2007 339 341
83. M. Terenziani, L. Piva, C. Meazza, L. Gandola, G. Cefalo, and M. Merola Oophoropexy: a relevant role in preservation of ovarian function after pelvic irradiation Fertil Steril 91 2009 935
84. Z. Blumenfeld, E. Dann, I. Avivi, R. Epelbaum, and J.M. Rowe Fertility after treatment for Hodgkin's disease Ann Oncol 13 2002 138 147
85. B. Pereyra Pacheco, J.M. Méndez Ribas, G. Milone, I. Fernández, R. Kvicala, and T. Mila Use of GnRH analogs for functional protection of the ovary and preservation of fertility during cancer treatment in adolescents: a preliminary report Gynecol Oncol 81 2001 391 397
86. F. Recchia, G. Saggio, G. Amiconi, A. Di Blasio, A. Cesta, and G. Candeloro Gonadotropin-releasing hormone analogues added to adjuvant chemotherapy protect ovarian function and improve clinical outcomes in young women with early breast carcinoma Cancer 106 2006 514 523
87. Z. Blumenfeld, I. Avivi, A. Eckman, R. Epelbaum, J.M. Rowe, and E.J. Dann Gonadotropin-releasing hormone agonist decreases chemotherapy-induced gonadotoxicity and premature ovarian failure in young female patients with Hodgkin lymphoma Fertil Steril 89 2008 166 173
88. K. Oktay, M. Sönmezer, O. Oktem, K. Fox, G. Emons, and H. Bang Absence of conclusive evidence for the safety and efficacy of gonadotropin-releasing hormone analogue treatment in protecting against chemotherapy-induced gonadal injury Oncologist 12 2007 1055 1066
89. A.N. Andersen, V. Goossens, A.P. Ferraretti, S. Bhattacharya, R. Felberbaum, and J. de Mouzon Assisted reproductive technology in Europe 2004 results generated from European registers by ESHRE Hum Reprod 23 2008 756 771
90. C. Basille, S. Fay, L. Hesters, N. Frydman, and R. Frydman In vitro fertilization (IVF): why doing it in unstimulated cycles? Gynecol Obstet Fertil 35 2007 877 880
91. A. Castelo-Branco, N. Frydman, J. Kadoch, A. Le Du, H. Fernandez, and R. Fanchin The role of the semi natural cycle as option of treatment of patients with a poor prognosis for successful in vitro fertilization J Gynecol Obstet Biol Reprod (Paris) 33 2004 518 524
92. K. Oktay, E. Buyuk, O. Davis, I. Yermakova, L. Veek, and Z. Rosenwaks Fertility preservation in breast cancer patients: IVF and embryo cryopreservation after ovarian stimulation with tamoxifen Hum Reprod 18 2003 90 95
93. K. Oktay, A. Hourvitz, G. Sahin, O. Oktem, B. Safro, and A. Cil Letrozole reduces estrogen and gonadotrpin exposure in women with breast cancer undergoing ovarian stimulation before chemotherapy J Clin Endocrinol Metab 91 2006 3885 3890
94. C. Chen Pregnancy after human oocyte cryopreservation Lancet 1 1986 884 886
95. K. Oktay, A.P. Cil, and H. Bang Efficiency of oocyte cryopreservation: a meta-analysis Fertil Steril 86 2006 70 80
96. L.L. Kuleshova, and A. Lopata Vitrification can be more favorable than slow cooling Fertil Steril 78 2002 449 454
97. L. Kuleshova, L. Gianaroli, C. Magli, A. Ferraretti, and A. Trounson Birth following vitrification of a small number of human oocytes: case report Hum Reprod 14 1999 3077 3079
98. M. Kuwayama, and G. Vatja Highly efficient vitrification method for cryopreservation of human oocytes Reprod Biomed Online 11 2005 300 308
99. M. Antinori Crytop vitrification og human oocytes results in high survival rate and healthy deliveries Reprod Biomd Online 14 2007 73 79
100. J. Donnez, M.M. Dolmans, D. Demylle, P. Jadoul, C. Pirard, and J. Squifflet Livebirth after orthotopic transplantation of cryopreserved ovarian tissue Lancet 364 2004 1405 1410 (Pubitemid 39370715)
101. D. Meirow, J. Levron, T. Eldar-Geva, I. Hardan, E. Fridman, and Y. Zalel Pregnancy after transplantation of cryopreserved ovarian tissue in a patient with ovarian failure after chemotherapy N Engl J Med 353 2005 318 321
102. I. Demeestere, P. Simon, S. Emiliani, A. Delbaere, and Y. Englert Fertility preservation: successful transplantation of cryopreserved ovarian tissue in a young patient previously treated for Hodgkin's disease Oncologist 12 2007 1437 1442
103. C.Y. Andersen, M. Rosendahl, A.G. Byskov, A. Loft, C. Ottosen, and M. Dueholm Two successful pregnancies following autotransplantation of frozen/thawed ovarian tissue Hum Reprod 23 2008 2266 2272
104. S.J. Silber, M. DeRosa, J. Pineda, K. Lenahan, D. Grenia, and K. Gorman A series of monozygotic twins discordant for ovarian failure: ovary transplantation (cortical versus microvascular) and cryopreservation Hum Reprod 23 2008 1531 1537
105. M.J. O'Brien, J.K. Pendola, and J.J. Eppig A revised protocol for in vitro development of mouse oocytes from primordial follicles dramatically improves their developmental competence Biol Reprod 68 2003 1682 1686
106. A. Gougeon Regulation of ovarian follicular development in primates: facts and hypotheses Endocr Rev 17 1996 121 155
107. M.L. Reuss, J. Kline, R. Santos, B. Levin, and I. Timor-Tritsch Age and the ovarian follicle pool assessed with transvaginal ultrasonography Am J Obstet Gynecol 174 1996 624 627
108. M.Y. Chang, C.H. Chiang, T.T. Hsieh, Y.K. Soong, and K.H. Hsu Use of the antral follicle count to predict the outcome of assisted reproductive technologies Fertil Steril 69 1998 505 510
109. L.F. Bancsi, F.J. Broekmans, M.J. Eijkemans, F.H. de Jong, J.D. Habbema, and E.R. te Velde Predictors of poor ovarian response in in vitro fertilization: a prospective study comparing basal markers of ovarian reserve Fertil Steril 77 2002 328 336
110. W.Q. Long, V. Ranchin, P. Pautier, C. Belville, P. Denizot, and H. Cailla Detection of minimal levels of serum anti-mullerian hormone during follow-up of patients with ovarian granulosa cell tumor by means of a highly sensitive enzyme-linked immunosorbent assay J Clin Endocrinol Metab 85 2000 540 544
111. M.M. Lee, P.K. Donahoe, T. Hasegawa, B. Silverman, G.B. Crist, and S. Best Mullerian inhibiting substance in humans: normal levels from infancy to adulthood J Clin Endocrinol Metab 81 1996 571 576
112. A. de Vet, J.S. Laven, F.H. de Jong, A.P. Themmen, and B.C. Fauser Anti-mullerian hormone serum levels: a putative marker for ovarian aging Fertil Steril 77 2002 357 362
113. D.B. Seifer, D.T. MacLaughlin, B.P. Christian, B. Feng, and R.M. Shelden Early follicular serum mullerian-inhibiting substance levels are associated with ovarian response during assisted reproductive technology cycles Fertil Steril 77 2002 468 471
114. I.A. van Rooij, F.J. Broekmans, E.R. te Velde, B.C. Fauser, L.F. Bancsi, and F.H. de Jong Serum anti-mullerian hormone levels: a novel measure of ovarian reserve Hum Reprod 17 2002 3065 3071
115. R. Fanchin, L.M. Schonauer, C. Righini, J. Guibourdenche, R. Frydman, and J. Taieb Serum anti-mullerian hormone is more strongly related to ovarian follicular status than serum inhibin B, estradiol, FSH and LH on day 3 Hum Reprod 18 2003 323 327
116. A. Münsterberg, and R. Lovell-Badge Expression of the mouse anti-mullerian hormone gene suggests a role in both male and female sexual differentiation Development 113 1991 613 624
117. T. Taketo, J. Saeed, T. Manganaro, M. Takahashi, and P.K. Donahoe Mullerian inhibiting substance production associated with loss of oocytes and testicular differentiation in the transplanted mouse XX gonadal primordium Biol Reprod 49 1993 13 23
118. C. Weenen, J.S. Laven, A.R. Von Bergh, M. Cranfield, N.P. Groome, and J.A. Visser Anti-mullerian hormone expression pattern in the human ovary: potential implications for initial and cyclic follicle recruitment Mol Hum Reprod 10 2004 77 83
119. L.E. Bath, W.H. Wallace, M.P. Shaw, C. Fitzpatrick, and R.A. Anderson Depletion of ovarian reserve in young women after treatment for cancer in childhood: detection by anti-mullerian hormone, inhibin B and ovarian ultrasound Hum Reprod 18 2003 2368 2374
120. D.S. Wachs, M.S. Coffler, P.J. Malcom, and R.J. Chang Serum anti-mullerian hormone concentrations are not altered by acute administration of follicle stimulating hormone in polycystic ovary syndrome and normal women J Clin Endocrinol Metab 92 2007 1871 1874
121. R. Fanchin, J. Taieb, H. Mendez Lozano, D. Ducot, B. Frydman, and R.J. Bouyer High reproducibility of serum anti-mullerian hormone measurements suggests a multi-staged follicular secretion and strengthens its role in the assessment of ovarian follicular status Hum Reprod 20 2005 923 927
122. W.J. Hehenkamp, C.W. Looman, A.P. Themmen, F.H. de Jong, E.R. Te Velde, and F.J. Broekmans Anti-mullerian hormone levels in the spontaneous menstrual cycle do not show substantial fluctuation J Clin Endocrinol Metab 91 2006 4057 4063
123. A. La Marca, G. Stabile, A.C. Artenisio, and A. Volpe Serum anti-mullerian hormone throughout the human menstrual cycle Hum Reprod 21 2006 3103 3107
124. I.A. van Rooij, I. Tonkelaar, F.J. Broekmans, C.W. Looman, G.J. Scheffer, and F.H. de Jong Anti-mullerian hormone is a promising predictor for the occurrence of the menopausal transition Menopause 11 2004 601 606
125. J. van Disseldorp, M.J. Faddy, A.P. Themmen, F.H. de Jong, P.H. Peeters, and Y.T. van der Schouw Relationship of serum anti-mullerian hormone concentration to age at menopause J Clin Endocrinol Metab 93 2008 2129 2134
126. M.R. Sowers, A.D. Eyvazzadeh, D. McConnell, M. Yosef, M.L. Jannausch, and D. Zhang Anti-mullerian hormone and inhibin B in the definition of ovarian aging and the menopause transition J Clin Endocrinol Metab 93 2008 3478 3483
127. K.L. Schmidt, C.Y. Andersen, A. Loft, A.G. Byskov, E. Ernst, and A.N. Andersen Follow-up of ovarian function post-chemotherapy following ovarian cryopreservation and transplantation Hum Reprod 20 2005 3539 3546
128. R.A. Anderson, A.P. Themmen, A. Al-Qahtani, N.P. Groome, and D.A. Cameron The effects of chemotherapy and long-term gonadotrophin suppression on the ovarian reserve in premenopausal women with breast cancer Hum Reprod 21 2006 2583 2592
129. K. Oktay, O. Oktem, A. Reh, and L. Vahdat Measuring the impact of chemotherapy on fertility in women with breast cancer J Clin Oncol 24 2006 4044 4046 (Pubitemid 46630768)
130. R.D. van Beek, M.M. van den Heuvel-Eibrink, J.S. Laven, F.H. de Jong, A.P. Themmen, and F.G. Hakvoort-Cammel Anti-mullerian hormone is a sensitive serum marker for gonadal function in women treated for Hodgkin's lymphoma during childhood J Clin Endocrinol Metab 92 2007 3869 3874
131. L. Giuseppe, G. Attilio, D.N. Edoardo, G. Loredana, L. Cristina, and L. Vincenzo Ovarian function after cancer treatment in young women affected by Hodgkin disease (HD) Hematology 12 2007 141 147
132. S. Lie Fong, P.J. Lugtenburg, I. Schipper, A.P. Themmen, F.H. de Jong, and P. Sonneveld Anti-mullerian hormone as a marker of ovarian function in women after chemotherapy and radiotherapy for haematological malignancies Hum Reprod 23 2008 674 678
133. G. Singh, N. Saxena, A. Aggarwal, and R. Misra Cytochrome P450 polymorphism as a predictor of ovarian toxicity to pulse cyclophosphamide in systemic lupus erythematosus J Rheumatol 34 2007 731 733
134. K. Takada, M. Arefayene, Z. Desta, C.H. Yarboro, D.T. Boumpas, and J.E. Balow Cytochrome P450 pharmacogenetics as a predictor of toxicity and clinical response to pulse cyclophosphamide in lupus nephritis Arthritis Rheum 50 2004 2202 2210
135. D.M. Parkin, F. Bray, J. Ferlay, and P. Pisani Estimating the world cancer burden: Globocan Int J Cancer 2001 94 2000 153 156